<DOC>
	<DOCNO>NCT00177372</DOCNO>
	<brief_summary>This pilot clinical trial evaluate whether medical management early pregnancy failure mifepristone misoprostol effective acceptable treatment . Subjects early pregnancy failure receive mifepristone follow 24 hour later vaginal misoprostol medical management . Subjects return study day 3 repeat ultrasound assess passage pregnancy tissue . subject still gestational sac present Day 3 receive second dose vaginal misoprostol . All subject follow-up Day 15 , phone pass pregnancy first dose misoprostol , person receive second dose . Questionnaires administer begin end study determine acceptability .</brief_summary>
	<brief_title>Mifepristone Misoprostol Fetal Demise</brief_title>
	<detailed_description />
	<mesh_term>Fetal Death</mesh_term>
	<mesh_term>Stillbirth</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>healthy hemodynamically stable female nonviable pregnancy orthostatic hypotension , contraindication either mifepristone misoprostol , treatment current pregnancy provide surgical medical evacuation uterus , evidence ovarian hyperstimulation syndrome , know suspect pelvic infection , know suspect clot defect receive anticoagulant , cardiovascular disease , current breastfeeding , pregnancy IUD situ , current participation another clinical trial , prior participation trial , suspect confirm endometrial AV malformation , clinical indication require karyotyping product conception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>